medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-12-100-104medsovet-2017Research ArticleДислипидемияDyslipidemiaРОЛЬ МОЩНЫХ СТАТИНОВ В СОВРЕМЕННОМ ЛЕЧЕНИИ БОЛЬНЫХ С ВЫСОКИМ РИСКОМ РАЗВИТИЯ ОСЛОЖНЕНИЙ, ОБУСЛОВЛЕННЫХ АТЕРОСКЛЕРОЗОМROLE OF POWERFUL STATINS IN MODERN TREATMENT OF PATIENTS WITH A HIGH RISK OF COMPLICATIONS ARISING FROM ATHEROSCLEROSISГиляревскийС. Р.GilyarevskijyS. R.

д.м.н., профессор

MD, Prof.

ГолшмидМ. В.GolshmidM. V.

к.м.н.

PhD in medicine

КузьминаИ. М.KuzminaI. M.

к.м.н.

PhD in medicine

Российская медицинская академия непрерывного профессионального образования; Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. МосквыРоссияRussian Medical Academy of Continuing Vocational Education; Sklifosovsky Emergency Research Institute of Emergency Medicine of the Moscow Healthcare DepartmentRussian FederationРоссийская медицинская академия непрерывного профессионального образования;РоссияRussian Medical Academy of Continuing Vocational Education;Russian FederationНаучно-исследовательский институт скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. МосквыРоссияSklifosovsky Emergency Research Institute of Emergency Medicine of the Moscow Healthcare DepartmentRussian Federation201703112017012100104Copyright © Гиляревский С.Р., Голшмид М.В., Кузьмина И.М., 20172017Гиляревский С.Р., Голшмид М.В., Кузьмина И.М.Gilyarevskijy S.R., Golshmid M.V., Kuzmina I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2017

В статье рассматриваются современные подходы к лечению больных с атеросклерозом, приводятся данные об эффективности применения новых классов гиполипидемических препаратов, а также обсуждается роль интенсивных режимов применения статинов на современном этапе гиполипидемической терапии. Приводятся доказательные данные об эффективности применения розувастатина для снижения концентрации холестерина липопротеинов низкой плотности в крови и снижения риска развития осложнений сердечно-сосудистых заболеваний, обусловленных атеросклерозом.

 

 

 

 

The article discusses modern approaches to the treatment of atherogenic patients, provides data on the effectiveness of new hypolipidemic drugs and discusses the role of intensive statin use regimes at the modern stage of the lipid-lowering therapy. Evidence is provided on the effectiveness of the use of rosuvastatin to reduce blodo LDL-cholesterol and to reduce the risk of cardiovascular disease complications caused by atherosclerosis.

гиполипидемическая терапиясердечно-сосудистые заболеванияобусловленные атеросклерозомэзетимибингибиторы PCSK9статинырозувастатинhypolipidemic therapycardiovascular diseases caused by atherosclerosisezetimibePCSK9 inhibitorsstatinsrosuvastatinReferencesStone NJ, Robinson JG, Lichtenstein AH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol, 2014, 63(25 pt B): 2889-2934.Stone NJ, Robinson JG, Lichtenstein AH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol, 2014, 63(25 pt B): 2889-2934.Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37: 2999-3058.Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37: 2999-3058.Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015, 372: 2387-2397.Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015, 372: 2387-2397.Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017, 376: 1713-1722.Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017, 376: 1713-1722.Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-2207.Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-2207.Cannon CP, Khan I, Klimchak AC et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease [published online August 2, 2017]. JAMA Cardiol, doi:10.1001 /jamacardio.2017.2289.Cannon CP, Khan I, Klimchak AC et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease [published online August 2, 2017]. JAMA Cardiol, doi:10.1001 /jamacardio.2017.2289.Virani SS, Akeroyd JM, Nambi V et al. Estimation of eligibility for PCSK9 inhibitors and associated costs based on the FOURIER trial: insights from the Department of Veterans Affairs. Circulation, 2017, 135: 2572-2574.Virani SS, Akeroyd JM, Nambi V et al. Estimation of eligibility for PCSK9 inhibitors and associated costs based on the FOURIER trial: insights from the Department of Veterans Affairs. Circulation, 2017, 135: 2572-2574.Smith SC Jr. Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels. JAMA Cardiol, 2017 Aug 2. doi: 10.1001/jamacardio.2017.2290. [Epub ahead of print].Smith SC Jr. Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels. JAMA Cardiol, 2017 Aug 2. doi: 10.1001/jamacardio.2017.2290. [Epub ahead of print].Kazi DS, Moran AE, Coxson PG et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA, 2016, 316: 743-753.Kazi DS, Moran AE, Coxson PG et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA, 2016, 316: 743-753.Kazi DS, Moran AE, Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy-reply. JAMA, 2016, 316: 2152.Kazi DS, Moran AE, Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy-reply. JAMA, 2016, 316: 2152.Svatikova A, Kopecky SL. Cholesterol Management in the Era of PCSK9 Inhibitors. Curr Cardiol Rep, 2017, 19: 83.Svatikova A, Kopecky SL. Cholesterol Management in the Era of PCSK9 Inhibitors. Curr Cardiol Rep, 2017, 19: 83.Anderson JL, Heidenreich PA, Barnett PG et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol, 2014, 63: 2304-2322.Anderson JL, Heidenreich PA, Barnett PG et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol, 2014, 63: 2304-2322.Tice JA, Kazi DS, Pearson SD. Proprotein con-vertase subtilisin/ kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern Med, 2016, 176: 107-108.Tice JA, Kazi DS, Pearson SD. Proprotein con-vertase subtilisin/ kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern Med, 2016, 176: 107-108.Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin, 2003, 19: 689-698.McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin, 2003, 19: 689-698.Pitt B, Loscalzo J, Monyak J et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol, 2012, 109: 1239-1246.Pitt B, Loscalzo J, Monyak J et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol, 2012, 109: 1239-1246.Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of sta-tin therapy. Lancet, 2016, 388: 2532-2561.Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of sta-tin therapy. Lancet, 2016, 388: 2532-2561.

The authors declare that there are no conflicts of interest present.